STOCK TITAN

Vanguard disaggregates holdings; Solventum (SOLV) Schedule 13G/A shows 0% ownership

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Solventum Corp: Amendment to Schedule 13G/A by The Vanguard Group reporting zero beneficial ownership. The filing amends prior disclosures to reflect an internal realignment at The Vanguard Group, stating that certain subsidiaries now report separately in reliance on SEC Release No. 34-39538. The filing lists 0 shares and 0% ownership of Common Stock.

Positive

  • None.

Negative

  • None.

Insights

Routine ownership update reflecting organizational disaggregation, not an economic stake change.

The filing records 0 shares and 0% beneficial ownership for The Vanguard Group after an internal realignment that caused certain subsidiaries to report separately under SEC Release No. 34-39538. This is an administrative reporting change rather than a transaction.

Cash‑flow treatment and trading activity are not stated; subsequent filings from the reporting entities may disclose holdings if applicable.

Amendment clarifies reporting structure under a specific SEC release; preserves compliance posture.

The amendment cites SEC Release No. 34-39538 and explains that disaggregated reporting follows an internal reorganization. It affirms that The Vanguard Group no longer claims beneficial ownership over securities reported by those subsidiaries.

Investors should note this is a disclosure alignment; no ownership percentage or share count that alters Solventum's capital structure is reported here.






83444M101

(CUSIP Number)
03/13/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/27/2026

FAQ

What does Solventum (SOLV) Schedule 13G/A Amendment No. 2 state about Vanguard's holdings?

It states that The Vanguard Group reports 0 shares and 0% beneficial ownership of Solventum common stock after an internal realignment, with certain subsidiaries to report separately under SEC Release No. 34-39538.

Why did The Vanguard Group amend its Schedule 13G/A for SOLV?

The amendment reflects an internal realignment effective January 12, 2026; subsidiaries that previously reported with The Vanguard Group will now report disaggregated ownership in reliance on SEC Release No. 34-39538, per the filing's explanatory comment.

Does the filing indicate any shares were bought or sold in Solventum (SOLV)?

No. The filing lists 0 shares beneficially owned and provides no transaction details; it is a reporting adjustment tied to organizational changes rather than a disclosed purchase or sale.

Who signed the amended Schedule 13G/A for Solventum (SOLV) and when?

The amendment is signed by Ashley Grim, Head of Global Fund Administration, with the signature date shown as 03/27/2026, certifying the filing under the stated organizational realignment.
Solventum Corporation

NYSE:SOLV

View SOLV Stock Overview

SOLV Rankings

SOLV Latest News

SOLV Latest SEC Filings

SOLV Stock Data

11.23B
147.50M
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
ST. PAUL